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SEVERE DISEASE? A PROSPECTIVE, OBSERVATIONAL STUDY
RICHARD M. JENNINGS, J. BRIAN DE SOUZA, JIM E. TODD, MARGARET ARMSTRONG, KATIE L. FLANAGAN,
ELEANOR M. RILEY, AND JUSTIN F. DOHERTY*
Hospital for Tropical Diseases, London, United Kingdom; London School of Hygiene and Tropical Medicine,
London, United Kingdom
Abstract. Just more than 2,000 cases of Plasmodium falciparum malaria are reported in the United Kingdom
annually, with a mortality rate of approximately 1%. Some studies suggest that patients with malaria who originate from
disease-endemic areas are less likely to develop severe disease; such patients are often treated at home. We have
prospectively examined 99 patients with imported P. falciparum malaria and categorized them according to severity as
defined by World Health Organization criteria. There was no significant difference between those who developed severe
disease and those who did not in terms of their ethnicity, residence in a malaria-endemic area, or history of previous
episodes of malaria. To assume a patient has clinical immunity to malaria simply because they originate from or have
lived for a long time in a malaria-endemic area may be inappropriate and unsafe.
INTRODUCTION
Plasmodium falciparum malaria accounts for 1–2 million
deaths each year, and more than 95% of these occur among
young African children.1 However, with increasing travel,
malaria is becoming a growing problem in temperate areas.
More than 2,000 cases of P. falciparum malaria are reported
in the United Kingdom each year, with a mortality rate of
approximately 1%;2 approximately 10% of these cases are
managed at the Hospital for Tropical Diseases in London.
Management of P. falciparum malaria varies widely in tem-
perate countries, and there has been considerable debate re-
cently about whether every patient with malaria should be
admitted to hospital.3 Patients with malaria may develop se-
rious complications;1 assessing the likelihood of development
of severe disease should be an important part of their initial
clinical management. People in malaria-endemic areas who
experience repeated malaria infections develop a degree of
immunity that confers some protection from clinical disease.4
Some patients with imported malaria may be expected to
have some degree of immunity, and others will be travelers
who have never previously been infected. It is often assumed
that people with imported malaria who have lived in malaria-
endemic regions may be less likely to develop complications.
Data from some previous studies have supported this assump-
tion.5–7 We have conducted a prospective study examining
the clinical, parasitologic, and immunologic characteristics of
P. falciparum infection in patients coming to the Hospital for
Tropical Diseases in London to determine whether those fac-
tors theoretically associated with immunity, namely residence
in a malaria-endemic area, previous infection with malaria,
and ethnicity, are associated with protection against severe
disease.
MATERIALS AND METHODS
Subjects. Patients coming to the Hospital for Tropical Dis-
eases between July 2000 and August 2002 with an episode of
confirmed P. falciparum malaria were invited to participate.
The study protocol was reviewed and approved by the Ethics
Committee of University College London Hospitals and
signed informed consent was obtained from each subject.
Study design. All subjects were admitted to hospital and
treated according to standard protocols, using oral or intra-
venous quinine followed by a second anti-malarial agent (usu-
ally sulfadoxine/pyrimethamine). Demographic and clinical
data were recorded at admission and daily thereafter onto a
standard pro-forma. Twenty milliliters of blood was taken
before any anti-malarial treatment was given for routine he-
matologic (full blood count) and biochemical (urea and elec-
trolytes and liver function tests) analyses, and repeated as
clinically indicated. Sera were stored from this admission
sample for immunoglobulin and cytokine assays. Malaria
films were taken daily, stained with Field’s stain, and exam-
ined at 1,000× magnification with the density of asexual in-
fection expressed as a percentage.
Outcome measures. There is no generally accepted defini-
tion of what constitutes immunity to malaria, nor is there any
laboratory marker that consistently predicts protection from
disease.4 As a result, we made no attempt to classify these
subjects as semi-immune or naïve. Rather, we divided the
study population into two groups, mild versus severe disease,
using modified World Health Organization criteria1 and then
looked for any differences between the groups in terms of
ethnicity, residence in a malaria-endemic area, previous his-
tory of malaria, or immunologic parameters that might be
expected to be associated with less severe disease.
Subjects were classified as having severe disease if any of
the following were present at any time: asexual parasitemia
> 2%, schizonts on the blood film, bilirubin > 20 IU/L, creati-
nine >130 mmol/L, hemoglobin < 9 g/dL, platelet count < 50 ×
109/L, or disease of sufficient severity to warrant admission to
the intensive therapy unit (ITU). The decision to admit to the
ITU was taken by attending physicians who were not other-
wise involved in the study. Patients with severe disease had an
average of 3.8 markers of severity, and their median parasit-
emia was 3.9%. All patients were monitored for hypoglyce-
mia while receiving quinine but hypoglycemia per se was not
taken as a marker of severe disease. Blood gas and lactate
measurements were not routinely made.
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Axillary temperature was measured at admission and every
four hours thereafter. The fever experienced by each subject
during their admission was expressed as a cumulative sum
around a value of 37.0°C.8 As an example, a temperature of
39°C scored +2 and a second reading of 36.5°C scored -0.5;
the final figure therefore represents the summation of each
temperature reading taken during the admission. Duration of
fever was taken as the number of days from the first recorded
fever to the beginning of the first 24-hour period without
fever (axillary temperature  37.5°C) irrespective of acet-
aminophen usage.
Immunologic parameters. Pro-inflammatory and anti-
inflammatory cytokines (tumor necrosis factor- [TNF-], in-
terleukin-10 [IL-10], interferon- [IFN-], and transforming
growth factor- [TGF-]) and antibodies against P. falci-
parum schizont extracts (Pfse) were measured by an enzyme-
linked immunosorbent assay (ELISA). Plasmodium falci-
parum schizonts obtained from Percoll purification were used
for preparing an antigen to detect antibody to P. falciparum
by standard capture ELISA as previously described.9 Plasma
concentrations of TNF- and TGF- were determined by
DuoSet ELISA (R&D Systems, Abingdon, United Kingdom)
according to manufacturers’ instructions. Monoclonal anti-
body pairs (Pharmingen-BD, Oxford, United Kingdom) were
used for determining the levels of IL-10 and IFN- as previ-
ously described.10 Plasma samples were tested in duplicate at
1:12 dilution for TGF- and at a dilution of 1:5 or 1:10 in all
other cytokine assays; cytokine concentrations were then cal-
culated per milliliter of undiluted plasma. All samples were
tested in duplicate and assays were repeated at least once on
different aliquots of each sample.
Statistical methods. The frequency and percentages for cat-
egorical variables were shown and differences between the
mild and severe groups were tested using the chi-square dis-
tribution. For continuous variables, means and standard de-
viations were shown for normally distributed data, and for
non-normal data (cytokine concentrations and duration data)
geometric means and ranges were presented. For the com-
parison of continuous data across mild and severe patients,
the T-test was used (on the log transformed data if necessary).
With 25 patients with severe disease and 75 patients with mild
disease, the study had 80% power to detect as significant an
odds ratio of 4.0 for common categorical exposures, a 70%
increase in IL-10 and IFN-, a 40% increase in TNF-, and a
30% increase in TGF-.
RESULTS
Ninety-nine patients with an average age of 39 years agreed
to take part in the study. None were pregnant. Thirty-seven
had taken anti-malarial prophylaxis and 19 had taken some
anti-malarial treatment before coming to the hospital. The
time between leaving a malaria-endemic area and coming to
hospital averaged 13 days. Of the 99 patients, all but four
acquired their infections in sub-Saharan Africa, and 53 of
these infections were acquired in either Nigeria or Ghana.
The other four patients acquired their infections in Cambo-
dia, India, Pakistan, and Vanuatu. Twenty-five patients had
severe disease as defined above. Of these 25, 24 acquired their
infection in sub-Saharan Africa and one in India. Patients
with severe disease each had on average 3.8 markers of se-
verity and a median parasitemia of 3.9% (Table 1). Twenty-
one had an asexual parasitemia >2%, 17 had schizonts on the
blood film, 24 had hyperbilirubinemia, 6 had an elevated cre-
atinine levels (4 of whom required dialysis), 7 had a hemo-
TABLE 1
Characteristics of patients classified as having severe malaria*
Ethnic origin Schizonts
Maximal
parasitemia, %
Bilirubin
> 20 mol/L
Creatinine
> 130 mol/L
Hemoglobin
< 9 g/dL
Platelet count
< 50 × 109/L ITU Dialysis
Exchange
transfused Died
Caucasian Yes 25 Yes No Yes Yes Yes No Yes No
Caribbean Yes 2.2 Yes No No Yes No No No No
Caucasian Yes 7.3 Yes No No Yes No No No No
Caucasian Yes 1.7 Yes No No No No No No No
Caucasian No 2 No No No No No No No No
Caucasian No 8.4 Yes Yes Yes Yes Yes Yes No No
Asian† Yes 2.1 Yes Yes Yes Yes Yes Yes Yes No
Asian† Yes 0.5 Yes Yes No Yes Yes No Yes No
Caucasian Yes 3.9 Yes Yes No Yes No No No No
African Yes 2.9 Yes No Yes No No No No No
African Yes 25 Yes No No No No No No No
African‡ Yes 0.01 Yes Yes Yes Yes Yes Yes No Yes
African No 0.3 Yes No No No No No No No
African§ Yes 25 Yes Yes Yes No Yes Yes No No
African No 2 Yes No Yes No No No No No
African Yes 3.9 Yes No No Yes No No No No
African Yes 2.5 Yes No No No No No No No
African Yes 17 Yes No No Yes No No No No
African Yes 3.2 Yes No No No No No No No
African No 4.5 Yes No No Yes No No No No
African No 4.8 Yes No No Yes No No No No
African Yes 18 Yes No No Yes No No No No
African No 3 Yes No No No No No No No
Caucasian No 30 Yes No No No No No No No
African Yes 4.2 Yes No No No No No No No
* ITU  intensive therapy unit.
† Asian patients from the Indian subcontinent.
‡ Patient with Glasgow coma score < 15 and requiring ventilatory support.
§ Patient required ventilatory support.
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globin concentration < 9 g/dL, and 13 had a platelet count <
50 × 109/L. Six required admission to the ITU, four of whom
had a history of previous exposure to malaria.
One patient, a 21-year-old Nigerian woman, died despite
admission to the ITU. She was born in Nigeria and lived there
until the age of 13. She made her first trip back to a malaria-
endemic area (Lagos) for eight years, and four days after
returning was admitted to hospital with cerebral malaria, re-
nal failure, and acute respiratory distress syndrome (ARDS).
As expected, the group with severe disease had a higher
maximal temperature, were febrile for longer, and required a
longer hospital stay, but there were few other differences
between the two groups. There was no difference between
those with severe disease compared with those with mild dis-
ease in terms of ethnicity, residence in a malaria-endemic
area, or previous history of malaria (as shown either by the
stated history of previous malaria or by the level of IgG an-
tibody to Pfse). These results are shown in Table 2. A higher
percentage of patients with mild disease reported taking anti-
malarial prophylaxis, and this difference was even greater
among those who reported taking prophylaxis in the last 28
days, although not reaching statistical significance (P 0.10).
Although IgG, IgM and IFN- levels tended to be lower in
severe cases than mild cases, these differences were not sta-
tistically significant. However, as expected, TNF- concentra-
tions were significantly higher in severe cases than mild cases;
there was also a tendency (although not statistically signifi-
cant) for IL-10 concentrations to be higher among severe
cases. Conversely, there was a significant inverse relationship
between the IgG antibody concentration to Pfse and highest
recorded parasitemia (correlation  -0.24, P  0.023) and
highest recorded temperature (correlation  -0.26, P 
0.016). This suggested that individuals with previous exposure
to malaria (i.e., those with anti-malarial antibodies) did have
some degree of anti-malarial immunity. Furthermore, IL-10
concentrations were significantly correlated with highest re-
corded parasitemia (n  41, correlation  0.30, P  0.05)
and temperature (n 39, correlation 0.36, P 0.025), and
TNF- concentrations were significantly associated with high-
est recorded parasitemia (n  90, correlation  0.49, P <
0.001) but not temperature (n 85, correlation 0.04, P
0.75).
DISCUSSION
The purpose of this study was to prospectively compare
patients with severe imported P. falciparum malaria with pa-
tients with mild disease in terms of their residential history,
ethnic origin, and history of previous malaria, factors assumed
to be associated with at least some degree of immunity to the
disease. We anticipated that adult patients who were born
and usually resident in sub-Saharan Africa (where almost all
the malaria infections in this study were acquired) might have
fewer parasites, less of an inflammatory response, and less
severe disease than individuals who had not previously been
exposed to malaria. However, there were no differences be-
tween the two groups in terms of any of these factors.
It is commonly believed that immunity to malaria is rapidly
lost once an individual moves away from a malaria-endemic
area, leaving previously immune individuals at high risk of
severe disease should they become re-infected.4 The one
death in this study, that of a Nigerian woman who was re-
exposed to malaria after eight years in Europe, could be seen
as an example of this. However, systematic surveys of malaria
in immigrants and during epidemics where malaria was rein-
TABLE 2
Demographic, clinical, and immunologic characteristics of patients with Plasmodium falciparum malaria, United Kingdom*
Characteristic
Malaria
Mild
n  74
Severe
n  25 Statistical value
Sex Male 50 (68%) 18 (72%) 2  0.17, P  0.7
Female 24 (32%) 7 (28%)
Age (years) Mean (SD) 39.8 (13.2) 37.9 (13.3) t  0.6, P  0.6
Ethnic background White 21 (28%) 7 (28%) 2df2  3.42, P  0.18
Black African 51 (69%) 15 (60%)
Other 2 (3%) 3 (12%)
Born in sub-Saharan Africa 50 (68%) 14 (56%) 2  1.09, P  0.3
Lived in malaria-endemic area 56 (76%) 20 (80%) 2  0.19, P  0.7
Reported previous malaria 44 (59%) 11 (44%) 2  1.81, P  0.2
Took malaria prophylaxis 30 (41%) 7 (28%) 2  1.26, P  0.3
Duration of symptoms before
admission (days)
Geometric mean† (range) 4.29 (1–60) 3.08 (1–10) T  1.63, P  0.11
Temperature at admission (oC) Mean (SD) 38.0 (1.16) 38.2 (1.19) T  0.69, P  0.5
Data from hospital stay
Length of admission (days) Geometric mean (range)† 2.69 (0–8) 5.18 (2–20) T  5.97, P < 0.001
Highest temperature (oC) Mean (SD) 38.4 (1.03) 38.9 (1.17) T  1.93, P  0.06
Cumulative sum Mean (SD) 6.05 (5.29) 9.09 (5.26) T  2.15, P  0.03
n 67 n 23
IgG (arbitrary units) Mean (SD) 1.15 (0.73) 0.91 (0.57) T  1.51, P  0.13
IgM (arbitrary units) Mean (SD) 0.75 (0.63) 0.53 (0.30) T  1.59, P  0.11
IFN- (pg/ml) Geometric mean (range) n 62, 4.39 (0.05–1244) n 20, 3.44 (0.3–37.1) T 0.53, P  0.6
IL 10 (pg/ml) Geometric mean (range) n 31, 33.37 (0.9–284) n 10, 77.21 (34.2–331) T  1.96, P  0.06
TNF- (pg/ml) Geometric mean (range) n 67, 29.56 (3.7–299) n  23, 58.3 (10.1–356) T  3.61, P < 0.001
TGF- (pg/ml) Geometric mean (range) (n 67), 4.86 (1.24–13.5) (n 23) 4.89 (1.67–19.8) T  0.01, P  0.95
* df  degrees of freedom; IFN-  inferferon-; IL  interleukin; TNF-  tumor necrosis factor-; TGF-  transforming growth factor-.
† Differences in geometric means tested on the natural log of the data.
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troduced after many years of effective control showed that
previously immune individuals, although they do become
sick, have significantly lower parasite densities and a lower
risk of severe and fatal outcomes than comparable, previously
naive individuals.11 Thus, our observation that a significant
proportion of visitors and recent immigrants to the United
Kingdom from malaria-endemic countries develop severe ma-
laria suggests that they have (or had) little or no pre-existing
functional immunity to malaria.
There is no marker that has reliably been shown to corre-
late with immunity to malaria, although there are inherent
resistance traits such as sickle-cell trait or other hemoglobino-
pathies4 that are known to be associated with protection
against severe disease. Precisely what constitutes immunity to
malaria is still much debated, but however it is defined, it is
mediated in part by pro-inflammatory and anti-inflammatory
cytokines, and there is evidence that these cytokines have a
prognostic role.12 In accordance with previous findings,13–16
high serum concentrations of TNF- and IL-10 were associ-
ated with higher parasite counts and more severe symptoms.
However, although anti-malarial antibody levels (which can
be viewed as a marker for previous exposure to malaria)17
were inversely correlated with maximal parasitemia, there
was no clear indication that antibody levels differed between
those with mild disease and those with severe disease. This is
consistent with the notion that malarial symptoms are in part
immune-mediated and that individuals with considerable pre-
vious exposure to malaria can still have severe disease.18
The prevalence of severe disease among malaria-exposed
adults in this study (26% of those who had ever lived in a
malaria-endemic area and 22% of those born in sub-Saharan
Africa had severe rather than mild malaria) might be consid-
ered rather high, given that most non-pregnant adults who
become infected with malaria in malaria-endemic areas de-
velop only trivial clinical disease and many people in malaria-
endemic areas have parasites in the blood without developing
any symptoms. However, the patients included in the present
study may not be representative of adult malaria infections in
general. Our patients are self-selected by virtue of the fact
that they have symptoms of sufficient severity to seek medical
care; it is possible that some cases of imported malaria in
immune individuals go unrecognized and unreported because
they have few clinical symptoms. Furthermore, African and
Asian patients who come to London with malaria will, by
definition, have access to sufficient resources to have traveled
to Europe and, by inference, may have previously lived in
more affluent areas and may not have had as much exposure
to the parasite as their less-advantaged compatriots. Both of
these considerations support the notion that most malaria
patients, wherever they originate from, who come to hospitals
in non-endemic countries are likely to have little effective
anti-malarial immunity.
This study raises some important points for the manage-
ment of imported P. falciparum malaria. First, malaria is not
a trivial disease. Six percent of our patients required admis-
sion to the ITU and one patient died after developing cere-
bral malaria complicated by ARDS and renal failure. Second
and more unexpectedly, severe disease was no less common
among patients who might be assumed to have a degree of
protective immunity than among previously malaria-naive pa-
tients. Many physicians managing cases of P. falciparum ma-
laria in temperate areas may assume that complications are
less likely to arise if the patient has lived in a malaria-endemic
region, as a result of some degree of acquired immunity. Our
study suggests that this assumption may not be valid.
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